RCS - Eco Animal Health Gp - EU launch of ECOVAXXIN® MS

ECO Animal Health

02/07/2026 07:00

RNS Number : 6956K
  
Eco Animal Health Group PLC
  
02 July 2026
  
 


2 July 2026

 
ECO Animal Health Group plc
("ECO" or the "Company")
 
EU launch of ECOVAXXIN® MS
 
ECO Animal Health Group plc (AIM: EAH), a leading global animal health company marketing and developing branded veterinary products to improve livestock productivity and welfare, announces the commercial launch of ECOVAXXIN® MS, its poultry vaccine against Mycoplasma synoviae (M. synoviae), across the European Union (EU) with its official launch event in Madrid, Spain.  
 
ECOVAXXIN® MS represents the first product from ECO's proprietary R&D pipeline to reach commercial market entry. The vaccine provides active immunisation of future layer and breeder chickens from four weeks of age, to reduce air-sac and foot-pad lesions and egg production losses caused by M. synoviae infections. The infection causes significant economic loss, particularly in laying hens, where egg production in affected layers can be reduced by 5-10%.
 
Andrew Buglass, Chief Commercial Officer of ECO Animal Health, commented: "ECOVAXXIN® MS is a best-in-class vaccine backed by an established EU commercial infrastructure and a network of committed distribution partners ready to reach producers at scale. We believe this will deliver meaningful clinical benefit for layer and breeder flocks across Europe and look forward to building on this commercial momentum across our launch markets."
 
ECO is leveraging its established commercial network, built for Aivlosin®, to deliver comprehensive market coverage with strategic distribution agreements in place across the major poultry markets in the EU, providing access to markets representing over 220 million layer-birds annually.
The Company is also progressing registration in USA, Latin American and Asian markets.  
-Ends-
 
Contacts
 




ECO Animal Health Group plc
David Hallas (Chief Executive Officer)
Christopher Wilks (Chief Financial Officer)
 


020 8447 8899




ICR Healthcare (Financial PR)
Mary-Jane Elliott
Jessica Hodgson
 


020 3709 5700
 




Singer Capital Markets (Nominated Adviser & Joint Broker)
Jen Boorer
Jalini Kalaravy
Samed Ethemi
 


020 7496 3000




Panmure Liberum (Joint Broker)
Emma Earl
Will Goode
Mark Rogers
Rupert Dearden
 


020 3100 2000 




Equity Development
Hannah Crowe
Matt Evans


020 7065 2692




 

About ECO Animal Health
ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.
 
Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.
 
Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.
 
Click here for more information: https://ecoanimalhealth.com
 
 




This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
NRAMZGGNRMGGVZM